Growth disorders

Lumos Pharma Announces OraGrowtH212 Trial of LUM-201 in PGHD Is Open for Enrollment

Retrieved on: 
Monday, June 28, 2021
Life sciences, Growth hormones, Health sciences, Hormones, Peptide hormones, Growth disorders, Specialty drugs, Growth hormone, Lumos, Biopharmaceutical

Lumos Pharma believes an increase in the pulsatile release of endogenous growth hormone (GH) has the potential to produce a substantial improvement in height velocity in PGHD patients.

Key Points: 
  • Lumos Pharma believes an increase in the pulsatile release of endogenous growth hormone (GH) has the potential to produce a substantial improvement in height velocity in PGHD patients.
  • We are excited to announce the opening of the OraGrowtH212 Trial said Rick Hawkins, CEO, President and Chairman of Lumos Pharma.
  • Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases.
  • Lumos Pharmas lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2b clinical trial, the OraGrowtH210 Trial, and a PK/PD clinical trial, OraGrowtH212 Trial, for the treatment of Pediatric Growth Hormone Deficiency (PGHD).

Newly Released Data on Three PGHD Patients Treated with LUM-201 in Prior Phase 2 Study To Be Presented in Lumos Pharma Key Opinion Leader Webinar

Retrieved on: 
Tuesday, April 27, 2021
Growth hormones, Endocrine system, Clinical medicine, Peptide hormones, Hormones, Growth disorders, Growth hormone therapy, Pediatrics, Growth hormone, Growth hormones, Endocrine system, Clinical medicine, Peptide hormones, Hormones, Growth disorders, Growth hormone therapy, Pediatrics, Growth hormone

Miller and Cassorla will be available to answer questions following the formal presentations.

Key Points: 
  • Miller and Cassorla will be available to answer questions following the formal presentations.
  • As has been previously disclosed in adults, LUM-201 increased the pulsatile release of growth hormone for 24 hours in Predictive Enrichment Marker (PEM) Positive subjects (N=2).
  • In children, this rare disorder is called pediatric growth hormone deficiency (PGHD).
  • LUM-201 has received Orphan Drug Designation in both the US and EU.\xc2\xa0For more information, please visit www.lumos-pharma.com .\n'

BioMarin Announces New and Updated Data at 2021 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting Demonstrating Commitment to Understanding Achondroplasia and Potential Treatment Choice

Retrieved on: 
Thursday, April 15, 2021
Growth disorders, Priority review, Achondroplasia, Medical specialties, Clinical medicine, Medicine

We look forward to further follow up over time in the extension study for additional insights on proportionality.

Key Points: 
  • We look forward to further follow up over time in the extension study for additional insights on proportionality.
  • "We are committed to understanding the potential lifetime impact of achondroplasia and providing information to support those interested in potential therapeutic options.
  • "\n"We believe it is critical for families with achondroplasia to be supported and have access to the resources they need for their children.
  • A PRV confers priority review to a subsequent drug application that would not otherwise qualify for that designation.

PRA’s remote patient monitoring platform selected by Merck KGaA, Darmstadt, Germany to work in combination with its human growth hormone treatment system

Retrieved on: 
Wednesday, April 7, 2021
Growth hormones, Clinical medicine, Medicine, Merck Group, Health care, Growth hormone therapy, Pediatrics, Recombinant proteins, Growth disorders, Serono, Growth hormone, Hormone therapy, Growth hormones, Clinical medicine, Medicine, Merck Group, Health care, Growth hormone therapy, Pediatrics, Recombinant proteins, Growth disorders, Serono, Growth hormone, Hormone therapy

RALEIGH, N.C. , April 07, 2021 (GLOBE NEWSWIRE) -- PRA Health Sciences (NASDAQ: PRAH) announced today that Merck KGaA, Darmstadt, Germany, known in the United States as EMD Serono, selected PRAs remote patient monitoring platform to work in combination with its human growth hormone (HGH) treatment system.

Key Points: 
  • RALEIGH, N.C. , April 07, 2021 (GLOBE NEWSWIRE) -- PRA Health Sciences (NASDAQ: PRAH) announced today that Merck KGaA, Darmstadt, Germany, known in the United States as EMD Serono, selected PRAs remote patient monitoring platform to work in combination with its human growth hormone (HGH) treatment system.
  • Human growth hormone treatments are frequently prescribed for children and adolescents with growth hormone deficiency, a condition that impacts approximately 1:4,000 to 1:10,000 children1 each year in the U.S.
  • Despite the prevalence of growth hormone deficiency and treatment options, one of the biggest challenges is ensuring patients adherence to the regimen.
  • PRA hosted a webinar called, How Digital Therapeutics and Remote Patient Monitoring Can Drive Pharmaceutical Product Differentiation, to help create differentiation.

Data Presented at ENDO 2021 Differentiate LUM-201 from Standard Growth Hormone Secretagogues and Further Support LUM-201’s Potential as a Therapeutic for Pediatric Growth Hormone Deficiency

Retrieved on: 
Saturday, March 20, 2021
Endocrine system, Growth hormones, Hormones, Organ systems, Peptide hormones, Growth disorders, Pediatrics, Growth hormone secretagogue, Growth hormone deficiency, Growth hormone, GH, Secretagogue

The poster can be viewed on the ENDO website and may also be found on the Companys website in the Investors & Media section, under Posters & Publications .

Key Points: 
  • The poster can be viewed on the ENDO website and may also be found on the Companys website in the Investors & Media section, under Posters & Publications .
  • Poster 7102 presents an analysis of data from a prior clinical study comparing the peak growth hormone (GH) response of LUM-201 (formerly MK-0677) to that of standard GH secretagogues (clonidine, arginine, L-dopa, glucagon, insulin) in children nave-to-treatment, previously diagnosed with growth hormone deficiency (GHD).
  • The objective was to determine whether LUM-201 stimulates GH responses different from standard GH secretagogues.
  • You should, therefore, not rely on these forward-looking statements as representingthe Companysviews as of any date subsequent to the date of this press release.

Lumos Pharma to Present Poster Demonstrating Greater GH Response to LUM-201 than to Standard GH Secretagogues in PGHD at the Endocrine Society (ENDO) 2021 Annual Meeting

Retrieved on: 
Tuesday, March 2, 2021
Growth hormones, Endocrine system, Hormones, Clinical medicine, Growth disorders, Peptide hormones, Growth hormone secretagogue, Growth hormone therapy, Growth hormone deficiency, Growth hormone, GH

AUSTIN, Texas, March 02, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, will present poster 7102 at the virtual Endocrine Society 2021 Annual Meeting, March 20th-23rd.

Key Points: 
  • AUSTIN, Texas, March 02, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, will present poster 7102 at the virtual Endocrine Society 2021 Annual Meeting, March 20th-23rd.
  • LUM-201 Elicits Greater GH Response than Standard GH Secretagogues in Pediatric Growth Hormone Deficiency will be presented by authors Bright, G., MD, et al.
  • on Saturday, March 20, 2021, at 11:00AM ET in Session P33 Growth and Growth Hormone.
  • At that time, the poster can be accessed in the Investors & Media section of our website on the Posters & Presentations page under Events & Presentations.

Global Acromegaly and Gigantism Markets to 2029: Top Selling Drug to Enter the Market will be Camurus' Octreotide LA

Retrieved on: 
Friday, December 4, 2020
Neuroendocrinology, Growth hormones, Growth disorders, Endocrinology, Medical specialties, Organ systems, Gigantism, Human height, Acromegaly, Octreotide, Camurus

DUBLIN, Dec. 4, 2020 /PRNewswire/ -- The "Acromegaly and Gigantism - Global Drug Forecast and Market Analysis to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Dec. 4, 2020 /PRNewswire/ -- The "Acromegaly and Gigantism - Global Drug Forecast and Market Analysis to 2029" report has been added to ResearchAndMarkets.com's offering.
  • The market is expected to grow at a CAGR of 4.4% from 2019 to 2029, reaching a global value of $2.2B.
  • While both acromegaly and gigantism are complications of uncontrolled GH levels, the presentation of the two hormonal diseases is very different.
  • The top selling drug to enter the market in the forecast period will be Camurus' octreotide LA, which is expected to become the first long-acting subcutaneously administrable formulation of octreotide.

$2.2 Billion Acromegaly and Gigantism Markets - Global Drug Forecast and Analysis to 2029 - ResearchAndMarkets.com

Retrieved on: 
Friday, November 27, 2020
Pharmaceutical, Genetics, Health, Other Health, Anatomy, Neuroendocrinology, Growth hormones, Branches of biology, Organ systems, Growth disorders, Endocrine system, Gigantism, Human height, Acromegaly, Growth hormone therapy, Growth hormone

The "Acromegaly and Gigantism - Global Drug Forecast and Market Analysis to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Acromegaly and Gigantism - Global Drug Forecast and Market Analysis to 2029" report has been added to ResearchAndMarkets.com's offering.
  • The market is expected to grow at a CAGR of 4.4% from 2019 to 2029, reaching a global value of $2.2B.
  • Acromegaly and gigantism are rare disorders of the pituitary gland characterized by the hypersecretion of growth hormone (GH).
  • While both acromegaly and gigantism are complications of uncontrolled GH levels, the presentation of the two hormonal diseases is very different.

2020 Market Study on Acromegaly and Gigantism with Epidemiology Forecast to 2029 - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 26, 2020
Health, Other Health, Anatomy, Neuroendocrinology, Growth hormones, Branches of biology, Organ systems, Growth disorders, Endocrine system, Acromegaly, Gigantism, Growth hormone therapy, Pituitary gland, Growth hormone

The "Acromegaly and Gigantism - Epidemiology Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Acromegaly and Gigantism - Epidemiology Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.
  • Acromegaly and gigantism are rare disorders of the pituitary gland, characterized by the hypersecretion of growth hormone (GH).
  • The report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of acromegaly and gigantism segmented by sex and age (ages 15 years and above in acromegaly cases, and all ages in gigantism cases).
  • The Acromegaly and Gigantism Epidemiology series will allow you to:
    Develop business strategies by understanding the trends shaping and driving the global acromegaly and gigantism market.

2020 Outlook on the Global Acromegaly Market - Epidemiology Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, October 16, 2020
Health, General Health, Neuroendocrinology, Organ systems, Growth disorders, Growth hormones, Acromegaly, RTT, Medical specialties, Endocrine system, Epidemiology

Develop business strategies by understanding the trends shaping and driving the 7MM Acromegaly epidemiology forecast.

Key Points: 
  • Develop business strategies by understanding the trends shaping and driving the 7MM Acromegaly epidemiology forecast.
  • The Acromegaly epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The proprietary Acromegaly epidemiology model is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies.
  • The report provides the segmentation of the disease epidemiology for 7MM by Total Prevalent Cases of Acromegaly, Total Diagnosed Prevalent Cases of Acromegaly, Origin Specific Cases of Acromegaly, and Diagnosed Cases of Acromegaly Based on Type of Adenomas.